24.1(top 1%)
2-year impact
1.9K(top 10%)
PR articles
125.6K(top 5%)
PR citations
171(top 2%)
PR h-index
178(top 2%)
h-index
23.7(top 1%)
2-YI (no self-cite.)
2.1K
documents
170.0K
doc citations

Top Articles

#TitleJournalYearCitations
1Ferroptosis, a new form of cell death: opportunities and challenges in cancerJournal of Hematology and Oncology20191,527
2Targeting the Wnt/β-catenin signaling pathway in cancerJournal of Hematology and Oncology20201,128
3Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applicationsJournal of Hematology and Oncology20191,086
4The biology and role of CD44 in cancer progression: therapeutic implicationsJournal of Hematology and Oncology20181,067
5Ferroptosis, necroptosis, and pyroptosis in anticancer immunityJournal of Hematology and Oncology2020983
6Nanomaterials for cancer therapy: current progress and perspectivesJournal of Hematology and Oncology2021925
7The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasisJournal of Hematology and Oncology2022827
8Recent advances in therapeutic strategies for triple-negative breast cancerJournal of Hematology and Oncology2022791
9Liquid biopsy: current technology and clinical applicationsJournal of Hematology and Oncology2022751
10Gastric cancer treatment: recent progress and future perspectivesJournal of Hematology and Oncology2023740
11Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis researchJournal of Hematology and Oncology2022723
12EZH2: a novel target for cancer treatmentJournal of Hematology and Oncology2020715
13Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapyJournal of Hematology and Oncology2019694
14Tumor-associated macrophages: from basic research to clinical applicationJournal of Hematology and Oncology2017689
15Targeting mTOR for cancer therapyJournal of Hematology and Oncology2019682
16The effects of β-glucan on human immune and cancer cellsJournal of Hematology and Oncology2009643
17Next generation of immune checkpoint therapy in cancer: new developments and challengesJournal of Hematology and Oncology2018629
18Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancerJournal of Hematology and Oncology2020625
19Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancersJournal of Hematology and Oncology2013614
20Exosomes in cancer: small particle, big playerJournal of Hematology and Oncology2015595
21Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinomaJournal of Hematology and Oncology2015582
22Cancer vaccines as promising immuno-therapeutics: platforms and current progressJournal of Hematology and Oncology2022577
23Challenges and advances in clinical applications of mesenchymal stromal cellsJournal of Hematology and Oncology2021573
24Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsJournal of Hematology and Oncology2019568
25Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapyJournal of Hematology and Oncology2023566
26NK cell-based cancer immunotherapy: from basic biology to clinical developmentJournal of Hematology and Oncology2021561
27Wnt/beta-catenin pathway: modulating anticancer immune responseJournal of Hematology and Oncology2017534
28Role of platelets and platelet receptors in cancer metastasisJournal of Hematology and Oncology2018527
29cGAS-STING, an important pathway in cancer immunotherapyJournal of Hematology and Oncology2020525
30Regulation of PD-L1 expression in the tumor microenvironmentJournal of Hematology and Oncology2021518
31Roles of METTL3 in cancer: mechanisms and therapeutic targetingJournal of Hematology and Oncology2020508
32Combination strategies to maximize the benefits of cancer immunotherapyJournal of Hematology and Oncology2021508
33The interplay between m6A RNA methylation and noncoding RNA in cancerJournal of Hematology and Oncology2019491
34Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacyJournal of Hematology and Oncology2019488
35Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentJournal of Hematology and Oncology2018485
36SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19Journal of Hematology and Oncology2020485
37Emerging role of exosomes in cancer progression and tumor microenvironment remodelingJournal of Hematology and Oncology2022483
38Immunosuppressive cells in cancer: mechanisms and potential therapeutic targetsJournal of Hematology and Oncology2022474
39Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapyJournal of Hematology and Oncology2019467
40Applications of single-cell sequencing in cancer research: progress and perspectivesJournal of Hematology and Oncology2021457
41Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapyJournal of Hematology and Oncology2020441
42Neutrophils in cancer carcinogenesis and metastasisJournal of Hematology and Oncology2021440
43Isolation and characterization of exosomes for cancer researchJournal of Hematology and Oncology2020438
44Next generation of immune checkpoint inhibitors and beyondJournal of Hematology and Oncology2021429
45Metabolism, metabolites, and macrophages in cancerJournal of Hematology and Oncology2023422
46A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaJournal of Hematology and Oncology2018416
47Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapyJournal of Hematology and Oncology2022413
48Targeting mutant p53 for cancer therapy: direct and indirect strategiesJournal of Hematology and Oncology2021412
49Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategiesJournal of Hematology and Oncology2022412
50Hypoxia-inducible factors: master regulators of hypoxic tumor immune escapeJournal of Hematology and Oncology2022409